Academic Publications. If the Applicant wishes to disseminate its Intellectual Property generated in the course of the Project for the purpose of scholarship, nothing in this Investment Agreement impedes such dissemination, provided the contributions of Alberta Innovates, the Ministry of Jobs, Economy and Innovation, the Government of Alberta, and the Funding Partners (if any) are acknowledged in such academic publication. Such publications may include, but are not limited to, abstracts, or presentations to a journal, editor, meeting, seminar or other third party.
Academic Publications. The Parties agree that it is part of the Applicant’s mission and policies to disseminate information and make it available for the purpose of scholarship, subject to the foregoing Section 11. Notwithstanding Section 11, the Applicant shall have the right to publish any Intellectual Property generated in the course of the Project in accordance with academic standards without restriction, provided the contributions of Alberta Innovates, the Ministry of Economic Development, Trade and Tourism, and the Government of Alberta are acknowledged in such academic publication. Such publications may include, but are not limited to, abstracts, or presentation to a journal, editor, meeting, seminar or other third party.
Academic Publications. The Principal Investigator and other members of the TAU Team shall have the right to publish the Ramot Technology and the Joint Technology in scientific publications or to present such results at scientific symposia, provided that the following procedure is followed:
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Lannett Intellectual Property that is subject to an Third Party Agreement, the parties to such Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Lannett has the right to review and comment on any such publications, Lannett shall, to the extent permissible under such Third Party Agreement, exercise such rights after consultation with HEC.
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Agios Intellectual Property that is subject to the Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Agios has the right to review and comment on any such publications, Agios shall, to the extent permissible under such Existing Third Party Agreement, exercise such rights after consultation with Celgene.
Academic Publications. The Principal Investigator and R&D Manager and other members of the AU Team shall have the right to publish the Ariel Technology in scientific publications or to present such results at scientific symposia, provided that the following procedure is followed:
Academic Publications. Licensors shall have the right to allow the Principal Investigators and other members of the Licensor Teams to publish the Research Results, if any, in scientific publications or to present such results at scientific symposia, provided that the following procedure is followed:
Academic Publications. The Parties agree that it is part of the Applicant’s mission and policies to disseminate information and make it available for the purpose of scholarship, subject to the foregoing Section
Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement, exercise such rights after consultation with Celgene.
Academic Publications. The Parties recognize that independent investigators have been engaged, and will be engaged in the future, to conduct clinical trials and studies of the Products. The Parties recognize that such investigators operate in an academic environment and may release information regarding such studies in a manner consistent with academic standards and as further provided in this paragraph. In the event that any such independent investigator of a Party desires to publish any abstract, manuscript or article or make any presentation (including verbal presentations) or other publication that includes any Confidential Information of the other Party, such Party shall (i) require such independent investigator to provide the other Party and its patent counsel the opportunity to review any proposed abstract, manuscript, article, presentation (including verbal presentations) or other publication at least thirty (30) days prior to its intended submission for publication or such presentation and (ii) upon request of the other Party not to submit any such abstract, article or manuscript for publication or not to make such presentation for such additional reasonable period of time (but not to exceed an additional thirty (30) days) to enable the other Party to secure patent protection for any material in such publication which it believes to be patentable or to consider the implications of publication on eventual commercialization.
